Free Trial
LON:MXCT

MaxCyte (MXCT) Share Price, News & Analysis

MaxCyte logo
GBX 266 +4.00 (+1.53%)
(As of 11/21/2024 ET)

About MaxCyte Stock (LON:MXCT)

Key Stats

Today's Range
262.25
269.20
50-Day Range
262
317
52-Week Range
259.14
430
Volume
6,689 shs
Average Volume
27,160 shs
Market Capitalization
£279.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock News Headlines

This MaxCyte Insider Increased Their Holding In The Last Year
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
MaxCyte Director Sells Shares Amid Active Trading
Craig-Hallum Sticks to Its Buy Rating for MaxCyte (MXCT)
See More Headlines

MXCT Stock Analysis - Frequently Asked Questions

MaxCyte's stock was trading at GBX 352.50 at the beginning of 2024. Since then, MXCT stock has decreased by 24.5% and is now trading at GBX 266.
View the best growth stocks for 2024 here
.

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), EQTEC (EQT), Grafton Group (GFTU), Lloyds Banking Group (LLOY) and Marks and Spencer Group (MKS).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Business Services
CIK
N/A
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Net Income
£-35,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£45.44 million
Cash Flow
GBX 134.89 per share
Book Value
GBX 211 per share

Miscellaneous

Free Float
N/A
Market Cap
£279.54 million
Optionable
Not Optionable
Beta
1.13
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (LON:MXCT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners